[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568386":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":20,"studyPopulation":13,"armGroups":21,"interventions":33,"overallOfficials":13,"centralContacts":43,"locations":53,"responsibleParty":72,"collaborators":13,"id":76,"slug":13,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":13,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":13,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":99,"whyStopped":13,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Sheikh Zayed Medical College","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Efficacy of oral voriconazole 200 mg once daily(low dose) vs. twice daily (high dose)","Efficacy will be assesssed clinically either through complete resolution of lesion or leaving behind pigmentation","Clinical assessment for efficacy will be done at day 14 and day 28",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE","Treatment of dermatophyte infection in our country is becoming difficult due to the developing resistance to traditional antifungal agents. Assessing the effectiveness and feasibility of a newer antifungal drug like voriconazole is the need of the hour in resistant cases.\n\nObjective: To compare the efficacy of oral 200 milligram voriconazole once a day vs twice a day in the treatment of resistant dermatophyte infections (tinea corporis and cruris).\n\nMaterial \\& Methods: This randomized controlled trial using non-probability sampling technique will be carried out in Outpatient Dermatology Department, Sheikh Zayed Hospital Rahim Yar Khan, Pakistan. Approval from ethical review committee of the hospital has been taken. Total 106 patients will be divided into two groups, Group A and Group B, each consisting of 53 patients. Group A will be given oral voriconazole 200mg once a day and Group B will be given twice a day for a maximum of 28 days. Efficacy will be assessed at day 14 and day 28, and relapse will be noted at the 2-month follow-up visit. Data will be recorded on a preformed Proforma for each patient and wiil be analyzed using SPSS 24. A p-value of less than 0.05 will be considered statistically significant.",[22,28],{"label":23,"type":24,"description":25,"interventionNames":26},"oral voriconazole 200 mg once daily group (group A)","ACTIVE_COMPARATOR","Patients with resistant dermatophyte infection (tinea corporis and cruris)will be given oral voriconazole 200 mg once daily",[27],"Drug: Voriconazole low dose",{"label":29,"type":24,"description":30,"interventionNames":31},"oral voriconazole 200 mg twice daily group (group B)","Patients with resistant dermatophyte infection (tinea corporis and cruris)will be given oral voriconazole 200 mg twice daily",[32],"Drug: Voriconazole high dose",[34,39],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":13},"DRUG","Voriconazole high dose","Oral voriconazole 200mg once a day for a maximum of 28 days",[29],{"type":35,"name":40,"description":41,"armGroupLabels":42,"otherNames":13},"Voriconazole low dose","Oral voriconazole 200mg twice a day for a maximum of 28 days",[23],[44,49],{"name":45,"role":46,"phone":47,"phoneExt":13,"email":48},"Muhammad Khurram Shahzad, FCPS dermatology","CONTACT","+923354847957","dr.khuram178@gmail.com",{"name":50,"role":46,"phone":51,"phoneExt":13,"email":52},"Tahir Hassan Hassan, FCPS Dermatology","+923364192737","drtahir.chandio@hotmail.com",[54],{"facility":55,"status":13,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Sheikh zayed Medical College and Hospital","Rahim Yar Khan","Punjab Province","64200","Pakistan","PK",{"type":62,"coordinates":63},"Point",[64,65],70.30345,28.41987,{"lat":65,"lon":64},[68],{"name":69,"role":46,"phone":70,"phoneExt":13,"email":71},"Sheikh zayed Medical college SZMC\u002FH","+92689230168","info@szmc.edu.pk",{"type":73,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"PRINCIPAL_INVESTIGATOR","Muhammad Khurram Shahzad","Senior Registrar Dermatology","100568386",false,"NCT06680544","Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections","Comparing the Efficacy of Oral 200 Milligram Voriconazole Once a Day Vs. Twice a Day in the Treatment of Resisitant Dermatophyte Infections (Tinea Corporis and Tinea Cruris)","Inclusion Criteria:\n\n1. Resistant cases of tinea cruris and tinea corporis: Those cases who received the standard dosage of oral antifungals i.e. oral terbinafine 5mg\u002Fkg per day for 4 weeks or oral itraconazole 5mg per\u002Fkg\u002Fday for 4 weeks but they did not recover from the infection.\n2. Skin area: Groin and trunk\n3. Total diameter of the lesions: 5cm to 80 cm\n\nExclusion Criteria:\n\n1. History of hypersensitivity to azoles\n2. All those individuals having immunocompromised state (malignancy, tuberculosis, AIDS, history of organ transplant and history of immunosuppressive drug treatment etc.)\n3. Patients of diabetes, liver or kidney disease.\n4. Lactating mother\n5. Pregnant female","ALL","18 Years","60 Years",{"count":86,"type":87},120,"ESTIMATED","INTERVENTIONAL",[90],"PHASE2","Treatment of dermatophyte infection in our country (Pakistan) is becoming difficult due to the developing resistance to traditional antifungal agents. Assessing the effectiveness ,feasibility and standard dosage of a newer antifungal drug like voriconazole is the need of the hour in resistant cases of dermatophyte infection.",[93],"Dermatophyte Infection",[95,96,97,98],"Tinea","Voriconazole","Dermatomycoses","Antifungal Agents","NOT_YET_RECRUITING","2024-11-07",{"date":102,"type":103},"2024-11-08","ACTUAL",{"date":105,"type":87},"2024-11-15",{"date":107,"type":87},"2025-03-15",{"name":5,"class":6},1]